Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer.

Life sciences - 15 Dec 2015

Guo Lu, Wu Hua, Zhu Jinghong, Zhang Caixia, Ma Jianxiu, Lan Jianfa, Xie Xiaodong

Abstract excerpt

AIMS: Cervical cancer is one of the most frequent malignant tumours in women. The PI3K/Akt pathway plays a role in chemoresistance to platinum-based neoadjuvant chemotherapy (NAC). The objective of this study was to evaluate the association between genetic polymorphisms in the PI3K/Akt pathway and chemotherapeutic outcomes following platinum-based NAC in Northwestern Chinese Han patients with squamous cervical...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Squamous Cell
Share to Cisplatin

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Class I Phosphatidylinositol 3-Kinases

Share to Neoadjuvant Therapy

Share to Phosphatidylinositol 3-Kinases

Share to Predictive Value of Tests

Share to Proto-Oncogene Proteins c-akt

Share to Uterine Cervical Neoplasms

Source

Identifiers

PMID: 26585822
DOI: 10.1016/j.lfs.2015.11.011

Genes

PTEN

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Genetic variations in the PI3K/AKT pathway predict platinum-based neoadjuvant chemotherapeutic sensitivity in squamous cervical cancer.PMID 26585822Read ↗

Machine learning-based models for genomic predicting neoadjuvant chemotherapeutic sensitivity in cervical cancerSemantic proximity Read ↗

Genetic alterations of PIK3CA and tumor response in patients with locally advanced cervical squamous cell carcinoma treated with cisplatin-based concurrent chemoradiotherapy.Semantic proximity Read ↗

Genetic variants in the PI3K/PTEN/AKT/mTOR pathway predict platinum-based chemotherapy response of advanced non-small cell lung cancers in a Chinese population.Semantic proximity Read ↗

Prognostic significance of PIK3CA mutation in stage IIB to IVA cervical cancers treated by concurrent chemoradiotherapy with weekly cisplatin.Semantic proximity Read ↗

Genome-wide association study identifies four SNPs associated with response to platinum-based neoadjuvant chemotherapy for cervical cancer.Semantic proximity Read ↗

Prevalence and Prognostic Significance of PIK3CA Mutation and CNV Status and Phosphorylated AKT Expression in Patients With Cervical Cancer Treated With Primary Surgery.Semantic proximity Read ↗

PIK3CA mutation and CNV status and post-chemoradiotherapy survival in patients with cervical cancer.Semantic proximity Read ↗

High incidence of PI3K pathway gene mutations in South Indian cervical cancers.Semantic proximity Read ↗

Transcriptome profiling of cervical cancer cells acquired resistance to cisplatin by deep sequencingSemantic proximity Read ↗

PI3K/PTEN/AKT/mTOR pathway genetic variation predicts toxicity and distant progression in lung cancer patients receiving platinum-based chemotherapy.Semantic proximity Read ↗

Genomic analysis of cervical carcinoma identifies Alpelisib as a therapeutic option for PIK3CA-mutant cervical carcinoma via the PI3K/AKT pathway.Semantic proximity Read ↗

Epidermal growth factor receptor pathway mutation and expression profiles in cervical squamous cell carcinoma: therapeutic implications.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.